Greenacre and Pecora elected to NeoStem board
This article was originally published in Scrip
NeoStem, a leader in the development and manufacture of cell therapies, has appointed Martyn Greenacre and Dr Andrew Pecora to its board. Mr Greenacre was previously chair of BMP Sunstone's board, and also served as a director of Cephalon. He is currently chair of the board of Acusphere and a director of Curis. From 1997 to 2001, Mr Greenacre was CEO and director of Delsys Pharmaceutical Corporation. Dr Pecora is co-founder and past chairman and CEO of PCT, now a NeoStem company. He currently serves as CMO of NeoStem, vice-president of cancer services and chief innovations officer of the John Theurer Cancer Center at Hackensack University Medical Center, and co-managing partner of the Northern Jersey Cancer Center.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.